Research Report on Southeast Asia Pharmaceutical Industry 2023-2032

Research Report on Southeast Asia Pharmaceutical Industry 2023-2032

With the rapid economic growth in Southeast Asia, the improvement of residents' living standards, the rise of the middle class, the aging of the population and the burden of non-communicable diseases, the demand for pharmaceutical consumption and medical and health expenditure in Southeast Asian countries are expanding. According to CRI 's analysis, the Southeast Asian pharmaceutical market has great potential for development.

Singapore has become the first stop for global pharmaceutical companies to enter Southeast Asia due to its comprehensive laws and regulations, mature regulatory system, and strong government support for the biopharmaceutical industry. Multinational companies such as AbbVie, Novartis, Pfizer, Roche, Sanofi and Abbott have built their production bases in Singapore to promote the development of the pharmaceutical industry in Southeast Asia.

Southeast Asia in this report includes 10 countries: Singapore, Thailand, Philippines, Malaysia, Indonesia, Vietnam, Myanmar, Brunei, Laos and Cambodia. With a total population of over 600 million by the end of 2021, Southeast Asia has an overall economic growth rate higher than the global average and is one of the key drivers of future global economic growth.

According to CRI's analysis, the economic levels of the 10 Southeast Asian countries vary greatly, with Singapore being the only developed country with a per capita GDP of about US$73,000 in 2021. While Myanmar and Cambodia will have a GDP per capita of less than US$2,000 in 2021. The population and minimum wage levels of each country also vary greatly. Brunei, which has the smallest population, will have a total population of less than 500,000 people in 2021, while Indonesia, which has the largest population, will have a population of about 275 million people in 2021.

CRI expects that the pharmaceutical industry in Southeast Asia will maintain growth from 2023-2032. On the one hand, the Southeast Asian pharmaceutical market has a lot of room for development and will attract more investment capital. On the other hand, Southeast Asian governments support the development of the pharmaceutical industry and have signed a number of free trade agreements to provide support for pharmaceutical companies to expand their export markets and develop distribution networks, promoting the development of the Southeast Asian pharmaceutical industry.

Topics covered:

• Southeast Asia Pharmaceutical Industry Status and Major Sources in 2018-2022 
• What is the Impact of COVID-19 on Southeast Asia Pharmaceutical Industry?
• Which Companies are the Major Players in Southeast Asia Pharmaceutical Industry Market and What are their Competitive Benchmarks?
• Key Drivers and Market Opportunities in Southeast Asia Pharmaceutical Industry
• What are the Key Drivers, Challenges, and Opportunities for Southeast Asia Pharmaceutical Industry during 2023-2032?
• What is the Expected Revenue of Southeast Asia Pharmaceutical Industry during 2023-2032?
• What are the Strategies Adopted by the Key Players in the Market to Increase Their Market Share in the Industry?
• What are the Competitive Advantages of the Major Players in Southeast Asia Pharmaceutical Industry Market?
• Which Segment of Southeast Asia Pharmaceutical Industry is Expected to Dominate the Market in 2032?
• What are the Major Adverse Factors Facing Southeast Asia Pharmaceutical Industry?